Breaking News

Catalent, Verastem Partner on Copiktra Capsules

FDA approves COPIKTRA capsules for relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent’s partner, Verastem Oncology, received approval from the FDA for Copiktra (duvelisib) capsules, an oral inhibitor of phosphoinositide 3-kinase (PI3K), for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies.   Copiktra also received accelerated approval for the treatment of relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. Continued approval for this indi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters